英夫利西单抗诱导后较高浓度与瘘管型克罗恩病临床结局改善相关:ACCENT-II事后分析
该研究为ACCENT-II试验的事后分析,评估瘘管型克罗恩病患者诱导期(n=282)和维持期(n=139)英夫利西单抗浓度与治疗结局的关联。多变量logistic回归显示,第14周较高英夫利西单抗浓度独立 associated 第14周瘘管应答和复合缓解,并与第54周复合缓解相关。ROC分析提示第2周≥20.2 μg/mL、第6周≥15 μg/mL、第14周≥7.2 μg/mL与第14周复合缓解相关。
要点
- 第14周英夫利西单抗浓度较高与第14周瘘管应答及复合缓解独立相关。
- 第14周浓度较高亦与第54周复合缓解独立相关。
- ROC分析提示第2周≥20.2 μg/mL、第6周≥15 μg/mL、第14周≥7.2 μg/mL与第14周复合缓解相关。
核心结论
- 瘘管型克罗恩病患者诱导后较高英夫利西单抗浓度与早期及长期有利治疗结局相关。
研究设计与样本
- ACCENT-II试验的事后分析,评估接受诱导治疗(n=282)和维持治疗(n=139)的瘘管型克罗恩病患者。
- 采用多变量logistic回归模型评估英夫利西单抗浓度与结局的关联。
主要发现
- 第14周较高英夫利西单抗浓度独立 associated 第14周瘘管应答(OR 1.16;95%CI 1.02-1.32;P=0.019)。
- 第14周较高英夫利西单抗浓度独立 associated 第14周复合缓解(OR 2.32;95%CI 1.55-3.49;P<0.001)。
- 第14周较高英夫利西单抗浓度独立 associated 第54周复合缓解(OR 2.05;95%CI 1.10-3.82;P=0.023)。
关键数值与推荐
- ROC曲线分析显示,与第14周复合缓解相关的第14周英夫利西单抗浓度阈值为:第2周≥20.2 μg/mL、第6周≥15 μg/mL、第14周≥7.2 μg/mL(综合最大敏感度和特异度)。
- 复合缓解定义为完全瘘管应答合并CRP正常化(CRP≤5 mg/L,适用于基线CRP升高患者)。
临床怎么用
- 对瘘管型克罗恩病患者,诱导期监测英夫利西单抗浓度可能有助于识别早期和长期结局不佳风险。
- 第2周、第6周和第14周的浓度阈值可作为达到复合缓解的参考。
局限性
- 本研究为ACCENT-II试验的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There are only limited data regarding the role of therapeutic drug monitoring in fistulizing Crohn's disease (CD). We investigated the association between both induction and maintenance serum infliximab concentrations and favorable therapeutic outcomes in patients with fistulizing CD. METHODS: This was a post hoc analysis of the ACCENT-II trial evaluating patients with fistulizing CD receiving induction (n = 282) and maintenance infliximab therapy (n = 139). Investigated therapeutic outcomes at both week 14 and week 54 included fistula response, complete fistula response, C-reactive protein (CRP) normalization (≤5 mg/L) in patients with an elevated baseline CRP, and a more stringent outcome of composite remission, defined as combined complete fistula response and CRP normalization. Associations between serum infliximab concentrations and outcomes were assessed by multivariable logistic regression models. RESULTS: Higher week 14 infliximab concentrations were independently associated with week 14 fistula response (odds ratio [OR]: 1.16; 95% confidence interval [CI]: 1.02-1.32; P = 0.019), and composite remission (OR: 2.32; 95% CI: 1.55-3.49; P < 0.001). Higher week 14 infliximab concentrations were also independently associated with week 54 composite remission (OR: 2.05; 95% CI: 1.10-3.82; P = 0.023). Based on receiver operating characteristic curve analysis, week 14 infliximab concentrations thresholds with combined maximal sensitivity and specificity of ≥20.2 μg/mL at week 2, ≥15 μg/mL at week 6, and ≥7.2 μg/mL at week 14 were associated with week 14 composite remission. DISCUSSION: Higher post-induction infliximab concentrations are associated with early and long-term favorable therapeutic outcomes in patients with fistulizing CD.
引用
- Papamichael K, Vande Casteele N, Jeyarajah J, et al. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol. 2021. PMID: 33929379. doi:10.14309/ajg.0000000000001111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。